Articles liés
FCNR(B) Deposit Rates: Canara Bank Offers Highest 3-Year USD FD Rate
Interest in Foreign Currency Non-Resident (FCNR) deposits has surged following an RBI concessional swap facility, attracting over USD 17.4 billion. Canara Bank offers the highest 3-year FCNR(B) USD fixed deposit rate at 6.50%, with other major Indian banks also providing competitive rates for NRIs, OCIs, and PIOs.
FSSAI Cracks Down on Misleading Food & Beverage Ads; 85% of Digital Ads Flagged by ASCI
India's FSSAI is cracking down on misleading health claims in food and beverage ads. Data from ASCI shows 85% of 158 digital ads flagged between January and June required changes, prompting FSSAI to issue notices.
Pakistan requests $10 billion exchange stabilization facility from U.S.
Pakistan has requested a $10 billion exchange stabilization facility from the U.S. to bolster foreign exchange reserves, ease pressure on the rupee, and reduce reliance on multilateral financing. This follows Pakistan's diplomatic role in Iran war talks and aims to deepen bilateral economic cooperation and attract U.S. investment.
Nike Restricts China Online Sales to Boost Brand Trust and Full-Price Strategy
Nike is restricting online sales by wholesale distributors in China, directing consumers to its own digital channels and emphasizing in-store sales from January. This strategy aims to rebuild shopper trust and sell products at full price amidst declining sales and strong domestic competition in its third-largest market.
India's Foreign Currency Mobilization Exceeds Expectations, RBI Data Shows
India's foreign-currency mobilization drive is surpassing initial forecasts, with the RBI reporting banks garnered $20.7 billion under its special incentive window. Economists now project an additional $10 billion upside, potentially reaching $80 billion in total flows, driven by FCNR(B) deposits and foreign bank participation.
Trump Announces Phased Tariffs on Imported Generic Medicines
US President Donald Trump announced a phased tariff regime on imported generic medicines, starting with zero duty for two years, then 100% for one year, and 200% thereafter, effective August 1, 2026. The policy aims to encourage domestic pharmaceutical manufacturing and protect US citizens.